Press

Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Apr 26 • 3 min read

Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, announced today that it has commenced dose administration of the first subject in a Phase I/IIa…

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its DMT and 5-MeO-DMT Drug Candidate Compounds

Apr 25 • 3 min read

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced today the filing of a new provisional patent application that covers new chemical entities (NCEs) that expand the Company’s next-generation…

Filament Health and Psyence Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products

Apr 22 • 4 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc (CSE: PSYG) (OTCQB: PSYGF) (“Psyence”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, today announced the conclusion of an exclusive licensing agreement with Psyence. Under…

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Apr 21 • 4 min read

Cybin Inc. (NEO: CYBN | NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that it has partnered with Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Company’s Phase 1/2a clinical trial of CYB003, a proprietary…

Nue Life Health, a Next-Gen Mental Wellness Platform, Announces a $23M Financing Led by Obvious Ventures and Western Technology Investment

Apr 20 • 4 min read

Nue Life Health, a breakthrough mental wellness company, today announced the completion of its Series A equity financing led by Obvious Ventures, as well as additional venture debt financing from Western Technology Investment, for a total funding of $23M. Founded in 2021, Nue Life offers an integrated therapeutic ecosystem of ketamine therapy, an interactive companion…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435